as financed its operations from public and private sales of equity, the exercise of warrants and stock options, and, to a lesser extent, interest income from funds available for investment, government grants, investment tax credits, and revenues from distribution, licensing and contract services. Since the Company does not have net earnings from its operations, the Company's long-term liquidity depends on its ability to access the capital markets, which depends substantially on the success of the Company's ongoing research and development programs.
At October 31, 2009, the Company had cash and cash equivalents totaling $23,540,000 (July 31, 2009 - $14,494,000). The increase in cash and cash equivalents in the first quarter of fiscal 2010 is the result of a private placement completed on September 8, 2009 where the Company issued 6,625,000 units at $2.05 per unit, for gross proceeds of $13,581,250. Each unit consists of one common share and one common share purchase warrant with each whole common share purchase warrant entitling the holder to purchase, subject to adjustment, one common share at a price of $2.87 until 5pm (Toronto time) on September 7, 2012. At October 31, 2009 the Company had outstanding 59,800,335 common shares; 10,025,000 warrants to purchase up to 10,025,000 common shares; and 3,564,000 incentive stock options to purchase up to 3,564,000 common shares.
At October 31, 2009, the Company's working capital was $23,425,000 (July 31, 2009 - $15,296,000).
Based on our planned expenditures and assuming no material unanticipated expenses, our forecasts indicate that our cash reserves and expected cash from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures to the end of fiscal 2011. These planned expenditures do not include those necessary to conduct the proposed U.S. Phase I and Polish Phase I/II clinical trials for L-DOS47 or the proposed U.S. Phase II/III andPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine technology :1
. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts2
. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory3
. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA4
. Helix BioPharma Corp. Announces Fiscal 2009 Results5
. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts6
. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO7
. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results8
. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months9
. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference10
. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis11
. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma